Company intelligence / Profile preview
ICM
Seoul, Seoul, South Koreaicm.org ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ICM is a South Korean biotech company leveraging an adeno-associated virus (AAV) gene therapy platform to develop treatments for incurable degenerative diseases. Their pipeline includes programs targeting osteoarthritis, age-related macular degeneration, and genetic forms of sensorineural hearing loss. The company positions itself as a developer of novel therapeutic solutions with a focus on restoring function in patients with currently untreatable conditions.
- Therapeutic areas
- RheumatologyOphthalmologyNeurology
- Modalities
- AAV gene therapyGene therapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on ICM.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ICM.